SC 13G/A - Haymaker Acquisition Corp. 4 (0001970509) (Subject)

SC 13G - Haymaker Acquisition Corp. 4 (0001970509) (Subject)

SC 13G - biote Corp. (0001819253) (Subject)

SC 13G - Haymaker Acquisition Corp. III (0001819253) (Subject)

SC 13G - Haymaker Acquisition Corp. III (0001819253) (Subject)

SC 13G - Haymaker Acquisition Corp. III (0001819253) (Subject)

SC 13G/A - Haymaker Acquisition Corp. II (0001771908) (Subject)

10-Q - Haymaker Acquisition Corp. 4 (0001970509) (Filer)

8-K - Haymaker Acquisition Corp. 4 (0001970509) (Filer)

10-Q - Haymaker Acquisition Corp. 4 (0001970509) (Filer)

8-K - Haymaker Acquisition Corp. 4 (0001970509) (Filer)

10-Q - Haymaker Acquisition Corp. 4 (0001970509) (Filer)

10-K - Haymaker Acquisition Corp. 4 (0001970509) (Filer)

424B4 - biote Corp. (0001819253) (Filer)

EFFECT - biote Corp. (0001819253) (Filer)

S-1/A - biote Corp. (0001819253) (Filer)

S-1 - biote Corp. (0001819253) (Filer)

NEW YORK, Sept. 12, 2023 /PRNewswire/ -- Haymaker Acquisition Corp. 4 (NYSE:HYAC) (the "Company") announced today that, commencing September 15, 2023, holders of the units sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the New York Stock Exchange under the symbols "HYAC" and "HYAC WS," respectively. Those units not separated will continue to trade on the New York Stock Exchange under the symbol "HYAC U." This press

Business combination with Haymaker Acquisition Corp. III complete biote Corp.'s common stock will trade on the Nasdaq Stock Exchange under ticker symbol "BTMD" biote Corp., (NASDAQ:BTMD) ("Biote" or the "Company"), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has completed its business combination with Haymaker Acquisition Corp. III (NASDAQ:HYAC) ("Haymaker"), a special purpose acquisition company. The business combination, which was approved by Haymaker's stockholders at its special meeting held on May 24, 2022, as well as the credit facilities entered into in connection with the closing of the business co

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. III (NASDAQ:HYAC) ("Haymaker" or the "Company"), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the "Business Combination") with Biote, and the related proposals, at Haymaker's special meeting held on May 24, 2022. A Form 8-K disclosing the full voting results has been filed with the Securities and Exchange Commission. The closing of the Business Combination is anticipated to take place on or about May 26, 2022. Following closing of the Business Combination, the common stock and warrants of the combined comp

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. III (NASDAQ:HYAC) ("Haymaker" or the "Company"), a publicly traded special purpose acquisition company, reminds its shareholders to vote in favor of the proposed business combination with BioTE Holdings, LLC ("Biote") and the related proposals at Haymaker's special meeting. The Company believes that all conditions to closing, including the minimum cash condition, have been or will be satisfied or waived. The special meeting will be held at 10:00 a.m. Eastern time, on May 24, 2022, via live webcast at the following address: https://www.cstproxy.com/haymakeracquisitioniii/2022 Haymaker's shareholders of record as of t

Record net sales of $139.4 million for the full year, a 20% increase year-over-year.Record net sales of $37.5 million in the fourth quarter, a 22% increase period-over-period.EBITDA of $36 million, a 9% increase year-over-year.¹In December 2021, Biote entered into a business combination agreement with Haymaker Acquisition Corp. III (NASDAQ:HYAC), which is expected to close in the second quarter of 2022.2022 guidance of $160-166 million in revenue and $46-50 million in EBITDA.¹ IRVING, Texas, March 22, 2022 (GLOBE NEWSWIRE) -- Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced record financial results for the fourt

Record net sales of $139.4 million for the full year, a 20% increase year-over-year. Record net sales of $37.5 million in the fourth quarter, a 22% increase period-over-period. EBITDA of $36 million, a 9% increase year-over-year.1 In December 2021, Biote entered into a business combination agreement with Haymaker Acquisition Corp. III (NASDAQ:HYAC), which is expected to close in the second quarter of 2022. 2022 guidance of $160-166 million in revenue and $46-50 million in EBITDA.1 Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced record financial results for the fourth quarter and full year of 2021. Bio

 Biote is a high-growth medical practice-building company operating within the multi-billion dollar hormone optimization space. Biote-certified practitioners provide personalized therapies to their patients who experience hormone imbalances. Biote is an established company with projected revenue of $136 million and Adjusted EBITDA of $38 million for 2021 and forecasted revenue of $160-166 million and Adjusted EBITDA of $46-50 million for 2022. The implied initial equity value of the business combination is approximately $737 million, with the combined company expected to have $195 million in cash after closing, assuming no Haymaker stockholders elect to have their shares redeemed. The

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. II (NASDAQ: HYAC) (“Haymaker”), a publicly traded special purpose acquisition company and ARKO Holdings Ltd. (“Arko Holdings”), an Israeli public holding company (TASE: AKHO) whose primary asset is a controlling stake in GPM Investments, LLC (“GPM”), a rapidly growing leader in the U.S. convenience store industry, announced today that they have satisfied all closing conditions and completed their previously announced business combination. Under the terms of the business combination agreement, Haymaker and Arko Holdings combined under a new company, ARKO Corp. (“ARKO”). Shares of ARKO common stock and ARKO warrants are e

  On Thursday, 94 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Medtronic (NYSE:MDT) was the biggest company on a market cap basis to set a new 52-week low. Performance Shipping (NASDAQ:PSHG) was the smallest company when considering market cap to set a new 52-week low. NRX Pharmaceuticals (NASDAQ:NRXP)'s stock came under the most pressure, trading down 63.34% to reach a new 52-week low. Centogene (NASDAQ:CNTG)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low. Stocks that set new 52-week lows on Thursday are as follows: Medtronic (NYSE:MDT) stock drifted down 4.4% on Thursday morning to hit a new 52-week low o

Haymaker Acquisition Corp. III (NASDAQ:HYAC) ("Haymaker" or the "Company"), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the "Business Combination") with Biote, and the related proposals, at Haymaker's special meeting held on May 24, 2022. A Form 8-K disclosing the full voting results has been filed with the Securities and Exchange Commission.   The closing of the Business Combination is anticipated to take place on or about May 26, 2022. Following closing of the Business Combination, the common stock and warrants of the combined company, called "biote Corp.," are expected to comm

Biote is a high-growth medical practice-building company operating within the multi-billion dollar hormone optimization space. Biote-certified practitioners provide personalized therapies to their patients who experience hormone imbalances. Biote is an established company with projected revenue of $136 million and Adjusted EBITDA of $38 million for 2021 and forecasted revenue of $160-166 million and Adjusted EBITDA of $46-50 million for 2022. The implied initial equity value of the business combination is approximately $737 million, with the combined company expected to have $195 million in cash after closing, assuming no Haymaker stockholders elect to have their shares redeemed. The bus

https://www.bloomberg.com/news/articles/2021-12-13/hormone-therapy-firm-biote-said-to-go-public-via-haymaker-spac

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)

4 - biote Corp. (0001819253) (Issuer)